Literature DB >> 8492317

The lifetime risk of developing breast cancer.

E J Feuer1, L M Wun, C C Boring, W D Flanders, M J Timmel, T Tong.   

Abstract

BACKGROUND: The lifetime risk of developing breast cancer in U.S. women, often quoted as one in nine, is a commonly cited cancer statistic. However, many estimates have used cancer rates derived from total rather than the cancer-free population and have not properly accounted for multiple cancers in the same individual.
PURPOSE: Our purpose was to provide a revised method for calculating estimates of the lifetime risk of developing breast cancer and to aid in interpretation of the estimates.
METHODS: A multiple decrement life table was derived by applying age-specific incidence and mortality rates from cross-sectional data to a hypothetical cohort of women. Incidence, mortality, and population data from 1975-1988 were used, representing the geographic areas of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. The incidence rates reflected only the first breast primary cancer; mortality rates reflected causes other than breast cancer. The population denominator used in calculating incidence rates was adjusted to reflect only those women without previously diagnosed breast cancers in the hypothetical cohort.
RESULTS: Our calculations showed an overall lifetime risk for developing invasive breast cancer of approximately one in eight with use of 1987-1988 SEER data, although up to age 85, it was still the commonly quoted one in nine.
CONCLUSION: Our estimate was calculated assuming constant age-specific rates derived from 1987-1988 SEER data. Because incidence and mortality rates change over time, conditional risk estimates over the short term (10 or 20 years) may be more reliable. A large portion of the rise in the lifetime risk of breast cancer estimated using 1975-1977 data (one in 10.6) to an estimate using 1987-1988 data (one in eight) may be attributed to 1) early detection of prevalent cases due to increased use of mammographic screening and 2) lower mortality due to causes other than breast cancer. A common misperception is that the lifetime risk estimate assumes that all women live to a particular age (e.g., 85 or 95). In fact, the calculation assumes that women can die from causes other than breast cancer at any possible age. Cutting off the lifetime risk calculation at age 85 assumes that no women develop breast cancer after that age. While the lifetime risk of developing breast cancer rose over the period 1976-1977 to 1987-1988, the lifetime risk of dying of breast cancer increased from one in 30 to one in 28, reflecting generally flat mortality trends.

Entities:  

Mesh:

Year:  1993        PMID: 8492317     DOI: 10.1093/jnci/85.11.892

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  99 in total

Review 1.  Structural cues from the tissue microenvironment are essential determinants of the human mammary epithelial cell phenotype.

Authors:  K L Schmeichel; V M Weaver; M J Bissell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

Review 2.  Effect of SERMs on breast tissue.

Authors:  S R Goldstein
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

Review 3.  Why should primary care physicians know about breast cancer genetics?

Authors:  L E Pinsky; J B Culver; J Hull; E Levy-Lahad; M Daly; W Burke
Journal:  West J Med       Date:  2001-09

4.  Improved population-based probability of developing cancer when direct estimates of the cancer-free population are available.

Authors:  Arianna Simonetti; Angela Mariotto; Martin Krapcho; Eric J Feuer
Journal:  Lifetime Data Anal       Date:  2012-03-20       Impact factor: 1.588

5.  One in four people may develop symptomatic hip osteoarthritis in his or her lifetime.

Authors:  L B Murphy; C G Helmick; T A Schwartz; J B Renner; G Tudor; G G Koch; A D Dragomir; W D Kalsbeek; G Luta; J M Jordan
Journal:  Osteoarthritis Cartilage       Date:  2010-08-14       Impact factor: 6.576

6.  Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.

Authors:  Sara Rodriguez-Acebes; Ian Proctor; Marco Loddo; Alex Wollenschlaeger; Mohammed Rashid; Mary Falzon; A Toby Prevost; Richard Sainsbury; Kai Stoeber; Gareth H Williams
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

7.  Racial and ethnic disparities in lifetime risk of corpus uterine cancer: a comparative study of Puerto Rico and the United States SEER population.

Authors:  Ana Patricia Ortiz; Yomayra Otero; Katherine Svensson; Omar García-Rodríguez; Sheyla Garced; Elvis Santiago; Sharee Umpierre; Nayda Figueroa; Karen J Ortiz-Ortiz
Journal:  Ethn Dis       Date:  2012       Impact factor: 1.847

8.  Epidemiology: Lifetime risk of diabetes mellitus--how high?

Authors:  Jaakko Tuomilehto; Suhad Bahijri
Journal:  Nat Rev Endocrinol       Date:  2016-01-04       Impact factor: 43.330

9.  Risk of ESRD in the United States.

Authors:  Patrick Albertus; Hal Morgenstern; Bruce Robinson; Rajiv Saran
Journal:  Am J Kidney Dis       Date:  2016-08-28       Impact factor: 8.860

10.  The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology.

Authors:  B Newman; P G Moorman; R Millikan; B F Qaqish; J Geradts; T E Aldrich; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.